DE69833451D1 - Behandlung der schizophrenie mit ampakinen und neuroleptika - Google Patents

Behandlung der schizophrenie mit ampakinen und neuroleptika

Info

Publication number
DE69833451D1
DE69833451D1 DE69833451T DE69833451T DE69833451D1 DE 69833451 D1 DE69833451 D1 DE 69833451D1 DE 69833451 T DE69833451 T DE 69833451T DE 69833451 T DE69833451 T DE 69833451T DE 69833451 D1 DE69833451 D1 DE 69833451D1
Authority
DE
Germany
Prior art keywords
schizophrenia
treatment
neuroleptika
ampakins
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69833451T
Other languages
English (en)
Other versions
DE69833451T2 (de
Inventor
A Johnson
A Rogers
S Lynch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Cortex Pharmaceuticals Inc
Original Assignee
University of California
Cortex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22050462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69833451(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California, Cortex Pharmaceuticals Inc filed Critical University of California
Application granted granted Critical
Publication of DE69833451D1 publication Critical patent/DE69833451D1/de
Publication of DE69833451T2 publication Critical patent/DE69833451T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69833451T 1997-10-27 1998-10-26 Behandlung der schizophrenie mit ampakinen und neuroleptika Expired - Lifetime DE69833451T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6362797P 1997-10-27 1997-10-27
US63627P 1997-10-27
PCT/US1998/022707 WO1999021422A1 (en) 1997-10-27 1998-10-26 Treatment of schizophrenia with ampakines and neuroleptics

Publications (2)

Publication Number Publication Date
DE69833451D1 true DE69833451D1 (de) 2006-04-20
DE69833451T2 DE69833451T2 (de) 2006-09-28

Family

ID=22050462

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69833451T Expired - Lifetime DE69833451T2 (de) 1997-10-27 1998-10-26 Behandlung der schizophrenie mit ampakinen und neuroleptika

Country Status (15)

Country Link
US (1) US6166008A (de)
EP (1) EP1026950B1 (de)
JP (1) JP2001520978A (de)
CN (1) CN1281335A (de)
AT (1) ATE317226T1 (de)
AU (1) AU745641B2 (de)
BR (1) BR9814106A (de)
CA (1) CA2306817A1 (de)
CY (1) CY1105557T1 (de)
DE (1) DE69833451T2 (de)
DK (1) DK1026950T3 (de)
ES (1) ES2258825T3 (de)
HK (1) HK1030338A1 (de)
PT (1) PT1026950E (de)
WO (1) WO1999021422A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE215079T1 (de) 1992-07-24 2002-04-15 Univ California Arzneimittel, die den durch ampa rezeptoren vermittelten synaptischen respons erhöhen
US20040229898A1 (en) * 2001-05-25 2004-11-18 The Regents Of The University Of California Cyclic bis-compounds clearing malformed proteins
WO2002096431A1 (en) * 2001-05-25 2002-12-05 The Regents Of The University Of California Optically active compounds clearing malformed proteins
AU2002324666B2 (en) * 2001-08-10 2007-10-11 The Rockefeller University Compostions and methods for modulation of DARPP-32 phosphorylation
UA80317C2 (en) * 2003-01-13 2007-09-10 Cortex Pharma Inc Method of treating cognitive decline due to sleep deprivation and stress
WO2005013961A1 (en) * 2003-07-17 2005-02-17 Eli Lilly And Company Combination therapy for treatment of cognitive disorders or psychoses
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
WO2005023182A2 (en) * 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
GB0325175D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
WO2005072345A2 (en) * 2004-01-26 2005-08-11 Cortex Pharmaceuticals Inc. Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors
AU2005258161B2 (en) 2004-06-21 2011-05-26 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
EP1809104A4 (de) * 2004-09-23 2009-04-29 Alexander Michalow Verfahren zum regeln von neurotransmittersystemen durch gegenadaptationen
AU2006216665A1 (en) * 2005-02-24 2006-08-31 Nicox S.A. Nitric oxide enhancing diuretic compounds, compositions and methods of use
KR101411167B1 (ko) 2005-04-13 2014-06-23 아스텍스 테라퓨틱스 리미티드 하이드록시벤즈아미드 유도체 및 hsp90 억제제로서의이의 용도
KR20060119373A (ko) * 2005-05-20 2006-11-24 엘지전자 주식회사 컴퓨터 시스템과 시스템 소프트웨어 설치방법 및 휴대용컴퓨터의 소프트웨어 설치방법
US20090233842A1 (en) 2005-11-12 2009-09-17 Prtzker Neuropsychiatric Research Fund Llc Fgf2-related methods for diagnosing and treating depression
US20090286797A1 (en) * 2005-11-22 2009-11-19 Dan Peters Novel Quinoxaline Derivatives and Their Medical Use
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
WO2008036282A1 (en) * 2006-09-18 2008-03-27 The Regents Of The University Of Californina Upregulating activity or expression of bdnf to mitigate cognitive impairment in asymptomatic huntington's subjects
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
JP5721949B2 (ja) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited 複合薬剤
US8779132B2 (en) 2006-10-12 2014-07-15 Astex Therapeutics Limited Pharmaceutical compounds
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
US20090006902A1 (en) * 2007-06-29 2009-01-01 International Business Machines Corporation Methods, systems, and computer program products for reporting fru failures in storage device enclosures
WO2009023126A2 (en) 2007-08-10 2009-02-19 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
WO2010087981A2 (en) * 2009-02-02 2010-08-05 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
PT105083A (pt) 2009-04-28 2011-07-25 Univ De Coimbra Processo para cultura de células estaminais neurais baseado nas ampacinas e/ou outros moduladores de receptores glutamatérgicos ionotrópicos, composições e seu uso em condições do sistema nervoso central
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
AU2012225784B2 (en) 2011-03-04 2016-03-17 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) * 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
ES2673872T3 (es) 2012-06-05 2018-06-26 The Board Of Trustees Of The Leland Stanford Junior University Mimético del péptido NCAM para su uso en el tratamiento de trastorno de depresión mayor
MA52288A (fr) 2018-04-18 2021-04-07 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci
CN112262143A (zh) 2018-05-21 2021-01-22 星座制药公司 甲基修饰酶的调节剂、其组合物和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5312819A (en) * 1990-08-20 1994-05-17 Sandoz Ltd. Pharmaceutical compositions comprising clozapine and a radical scavenger
US5447948A (en) * 1992-05-07 1995-09-05 Yale University Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
GB9507230D0 (en) * 1995-04-07 1995-05-31 Inst Of Psychiatry Novel method
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5773434A (en) * 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response

Also Published As

Publication number Publication date
ATE317226T1 (de) 2006-02-15
CN1281335A (zh) 2001-01-24
CY1105557T1 (el) 2010-07-28
ES2258825T3 (es) 2006-09-01
EP1026950B1 (de) 2006-02-08
PT1026950E (pt) 2006-06-30
AU1365899A (en) 1999-05-17
HK1030338A1 (en) 2001-05-04
CA2306817A1 (en) 1999-05-06
DE69833451T2 (de) 2006-09-28
EP1026950A1 (de) 2000-08-16
JP2001520978A (ja) 2001-11-06
AU745641B2 (en) 2002-03-28
DK1026950T3 (da) 2006-06-26
US6166008A (en) 2000-12-26
EP1026950A4 (de) 2004-07-07
BR9814106A (pt) 2000-10-03
WO1999021422A1 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
DE69833451D1 (de) Behandlung der schizophrenie mit ampakinen und neuroleptika
NO306779B1 (no) Naftalamider, anvendelse derav og farmasöytisk preparat
CY1115759T1 (el) Αντιβιοτικες συνθεσεις για θεραπεια του οφθαλμου
DE69429524T2 (de) Aminocyclohexylester und ihre anwendung
DE60024588D1 (de) Substituierte porphyrine und deren therapeutische verwendungen
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
ATE256671T1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)- piperazin-derivate
SV1999000102A (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa. ref. pcs 9475 afae/bb.
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ID25856A (id) Senyawa-senyawa baru
CA2284551A1 (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
DE60304695D1 (de) 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
DE69526584D1 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
TR200000916T2 (tr) İkameli piperidin türevleri.

Legal Events

Date Code Title Description
8363 Opposition against the patent